Clinical trial Recruiting at 1 site Interventional Ages 18 to 65

Long-term follow-up of MRI markers (central vein sign and paramagnetic rim lesions) in multiple sclerosis

Official title: Central Vein Sign in Multiple Sclerosis Extension Study

Run by The Cleveland Clinic · NCT07424027 · Data updated 2026-11-12

This project will test whether two MRI markers—the central vein sign (CVS) and paramagnetic rim lesions (PRL)—help diagnose and track people with multiple sclerosis over 48 months.

More Multiple Sclerosis trials

Quick facts

Study typeInterventional
Ages18 Years to 65 Years
SexAll
Enrollment40 (estimated)
SponsorThe Cleveland Clinic
Academic / other
Locations3 sites (Los Angeles, California and 2 other locations)
StatusRecruiting
StartedOctober 7, 2025
Main results expectedDecember 31, 2026
Study endsDecember 31, 2027
Registry record updatedFebruary 20, 2026
Trial IDNCT07424027 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults with suspected or confirmed multiple sclerosis who completed the original CAVS‑MS two‑year visits, can give informed consent, and can safely undergo MRI are the intended participants.

Probably not a fit

People who did not participate in the original CAVS‑MS, who have MRI contraindications (e.g., incompatible metal implants), or who cannot tolerate MRI (severe claustrophobia or excessive movement) are not eligible and are unlikely to benefit from this extension.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a 48-month extension of the CAVS‑MS effort that will follow 40 participants at three U.S. centers to collect serial MRIs and compare CVS and PRL findings over time. Participants who completed the 24‑month CAVS‑MS visit will undergo additional MRI visits, including contrast-enhanced sequences, to document lesion characteristics and changes. The study will measure how well CVS helps distinguish MS lesions from mimics and whether PRLs predict clinical course or lesion evolution. Results will provide pilot longitudinal data to inform a larger multicenter follow-up effort.

Why it matters

Potential benefit: If successful, these MRI markers could make diagnosis more accurate and help doctors monitor disease activity over time, which may lead to earlier or better-tailored treatment.

How similar studies have gone: Numerous cross-sectional studies have shown the CVS reliably distinguishes MS lesions from common mimics and PRLs are a promising marker, but long-term longitudinal data are still limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Participants must be enrolled in and meet all inclusion criteria of the CAVS-MS study.
* Must have participated in the CAVS-MS study and have completed month 24 visits.
* Able to provide written informed consent to participate in the study.

Exclusion Criteria:

* Contraindication to MRI studies; metal or metal implants incompatible with MRI
* Inability to tolerate MRI due to claustrophobia or known excessive movement (e.g. tremor).

Where it's running

  • Cleveland Clinic Foundation
    Cleveland, Ohio, United States
    Recruiting
  • Cedars-Sinai Medical Center
    Los Angeles, California, United States
    Not yet recruiting
  • University of Pennsylvania
    Philadelphia, Pennsylvania, United States
    Not yet recruiting

Study contacts

  • Principal investigator: Daniel Ontaneda, MD, PHD — The Cleveland Clinic
  • Study coordinator: Meghan Kilbane
  • Email: kilbanm@ccf.org
  • Phone: 216-445-9845

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.